Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 4,661 shares, a growth of 9,222.0% from the May 31st total of 50 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Approximately 0.0% of the shares of the company are sold short.
Innate Pharma Stock Performance
Shares of IPHYF remained flat at $1.65 during mid-day trading on Thursday. Innate Pharma has a 12-month low of $1.37 and a 12-month high of $2.25. The company’s 50-day simple moving average is $1.70 and its two-hundred day simple moving average is $1.89.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Featured Articles
- Five stocks we like better than Innate Pharma
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
